ImmunityBio, Inc. (IBRX) at a glance
ImmunityBio, Inc. (IBRX) is a mid-cap Healthcare company. It trades at $7.92, with a 99.3% profit margin and revenue growth of 167.6%. It does not pay a dividend. Vestovix scores it 73/100 overall. Its strongest dimension is Safety (99/100) and its weakest is Income (40/100). It is a relatively defensive holding with below-market volatility.
- Price
- $7.92
- Market cap
- $7.44B
- P/E ratio
- n/a
- Dividend yield
- None
- Beta
- 0.10
- 52-week range
- $1.95 to $12.43
Value
65
Growth
94
Income
40
Safety
99
Momentum
55
Other Healthcare stocks
See allDHR.PR.A50
Danaher Corp
$1,841.01+0.00%
2.58% yield
LLY68
Eli Lilly and Company
$1,116.20-0.96%
0.57% yield
JNJ61
Johnson & Johnson
$266.20+0.73%
2.18% yield
ABBV46
AbbVie Inc.
$257.12-0.86%
2.96% yield
UNH56
UnitedHealth Group Incorporated
$378.73-0.34%
2.16% yield
MRK60
Merck & Co., Inc.
$144.01-0.98%
2.79% yield
ABT54
Abbott Laboratories
$103.57+0.92%
2.16% yield
AMGN65
Amgen Inc.
$378.21-1.05%
2.76% yield